The biopharmaceutical company Petrovax Pharm has received a license from the Russian Ministry of Industry and Trade for the production of a meningococcal vaccine.
“Receiving the license is the next stage in implementing the project to localize vaccine production at the company’s facility in the Moscow region, which began in 2022. The total investment in the project exceeded 3 billion rubles,” GxP News was informed by the pharmaceutical manufacturer’s press service.
“We are ready to begin full-cycle production of the meningococcal vaccine, including substance synthesis As early as 2026, and we can meet 100% of the demand should it be included in the National Calendar of Vaccinations,” noted Mikhail Tsyferov, President of Petrovax Pharm.
The company expects to receive a registration certificate for a quadrivalent conjugated polysaccharide vaccine against meningococcal infection of serogroups A, C, Y, and W-135 this upcoming summer. Petrovax Pharm’s production capacity allows for the release of over 3.5 million vaccine doses annually.
